Governor Hochul Announces New Members of Emerging Technology Advisory Board for Biotechnology

Strategic Insights -

New York Governor Kathy Hochul today announced the new members of the Emerging Technology Advisory Board (ETAB) for biotechnology, an independent group of industry leaders tasked with helping chart the course to further expand a thriving biotech ecosystem in New York State. The advisory board, co-chaired by Pfizer Chief Strategy and Innovation Officer Andrew Baum and The Michael J. Fox Foundation CEO and Co-Founder Debi Brooks, will help further the Governor's commitment to making New York a national leader in life sciences, innovation, and advanced manufacturing.

The ETAB on Biotechnology includes leaders from business, philanthropy, and research institutions, reflecting New York's vast leadership and experience in the biotech sector. The group will focus on developing recommendations that support New York State's strategy in the emerging biotechnology landscape, including accelerating commercialization of advanced technologies and new therapeutics, unlocking private capital through public-private partnerships, supporting the development of AI in this sector, and strengthening workforce development. These recommendations will build on the Governor's investments in the state's life sciences ecosystem, which have totalled over $354 million.

Key Takeaways:

  • The Emerging Technology Advisory Board (ETAB) on Biotechnology is an independent group of industry leaders tasked with helping chart the course to further expand a thriving biotech ecosystem in New York State.
  • The advisory board is co-chaired by Pfizer Chief Strategy and Innovation Officer Andrew Baum and The Michael J. Fox Foundation CEO and Co-Founder Debi Brooks.
  • The ETAB on Biotechnology includes leaders from business, philanthropy, and research institutions, reflecting New York's vast leadership and experience in the biotech sector.
  • The group will focus on developing recommendations that support New York State's strategy in the emerging biotechnology landscape, including accelerating commercialization of advanced technologies and new therapeutics.
  • Governor Hochul has invested over $354 million in New York's life sciences ecosystem to support the advancement of medical science and drive the state's economy.
  • The Governor has also announced the opening of the Roswell Park GMP Engineering and Cell Manufacturing Facility, a $98 million cell and gene therapy hub in Buffalo.
  • The New York Biogenesis Park, a $430 million Cell and Gene Therapy Innovation Hub in Nassau County, Long Island, is also being developed with a historic $150 million state investment.

Statistics:

  • $354 million - Total investments in New York's life sciences ecosystem by Governor Hochul.
  • 98 million - Cost of the Roswell Park GMP Engineering and Cell Manufacturing Facility.
  • 150 million - State investment in New York Biogenesis Park.
  • 430 million - Cost of New York Biogenesis Park.
  • 1,500 - Direct jobs created by GlobalFoundries' $11.6 billion investment in the Capital Region.
  • 50,000 - New direct and indirect jobs created by Micron's 20-year, $100 billion investment in Central New York.

Sources:

  • The office of the Governor of New York
  • Governor Kathy Hochul's press release
  • New York Governor Kathy Hochul's innovation agenda
  • GlobalFoundries' press release
  • Micron's press release
  • The Michael J. Fox Foundation
  • Pfizer's press release